A Serum Metabolomic Study Reveals Changes in Metabolites During the Treatment of Lung Cancer-Bearing Mice with Anlotinib

BACKGROUND: Anlotinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor recommended for the treatment of advanced lung cancer patients after at least two previous systemic chemotherapies. Currently, many patients with lung cancer do not respond well to anlotinib treatment. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Xiaoting, Chen, Wenhao, Nie, Mengjun, Liu, Yuanjie, Xiao, Zuopeng, Zhang, Ying, Zhang, Wei, Zou, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349534/
https://www.ncbi.nlm.nih.gov/pubmed/34377024
http://dx.doi.org/10.2147/CMAR.S300897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349534/
https://www.ncbi.nlm.nih.gov/pubmed/34377024
http://dx.doi.org/10.2147/CMAR.S300897

Ejemplares similares